Samuel Constant
Plan, GR, Switzerland
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 64 publications
Key challenges for in vitro testing of oral tobacco and nicotine products for regulatory applications: Recommendations for using in vitro toxicity and disease models.
Journal: Alternatives to laboratory animals : ATLA
Published: August 14, 2026
A bovine H5N1 virus efficiently replicates in differentiated human nasal epithelial cells.
Journal: Npj viruses
Published: January 16, 2026
Cell-type specific effects of SARS-CoV-2 P252L mutation on nirmatrelvir sensitivity.
Journal: Antiviral research
Published: January 08, 2026
An innovative approach for anti-respiratory syncytial virus compound discovery from plant extracts, combining high-throughput screening and metabolomics.
Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
Published: October 17, 2025
Influenza A(H1N1)pdm09 virus resistance to baloxavir, oseltamivir and sialic acid mimetics in single and dual therapies: Insights from human airway epithelia and murine models.
Journal: Antiviral research
Published: October 25, 2024
Multidrug Combinations against SARS-CoV-2 Using GS-441524 or Ivermectin with Molnupiravir and/or Nirmatrelvir in Reconstituted Human Nasal Airway Epithelia.
Journal: Pharmaceutics
Published: July 30, 2024
Rheological comparison of sputum and reconstituted airway epithelium mucus.
Journal: Scientific reports
Published: July 10, 2024
The triple combination of Remdesivir (GS-441524), Molnupiravir and Ribavirin is highly efficient in inhibiting coronavirus replication in human nasal airway epithelial cell cultures and in a hamster infection model.
Journal: bioRxiv : the preprint server for biology
Published: May 27, 2024
Last Updated: 09/26/2026